<DOC>
	<DOCNO>NCT00632645</DOCNO>
	<brief_summary>Huntington 's disease ( HD ) autosomal dominant neurodegenerative disease , start average ( high variability ) fourth decade . The disease progression classically characterize cognitive deterioration ( cortical-frontal dementia ) , motor disorder ( associate chorea , dystonia bradykinesia ) , psychiatric disturbance ( combine depression irritability ) metabolic disorder ( cachexia ) . The disease fatal within 15 20 year patient . HD cure . Neuroleptics main drug use demonstrate efficacy chorea clinical trial . But neuroleptic also beneficial adverse effect disease characteristic ( motor , psychiatric , cognitive metabolic ) . Their profile beneficial adverse effect could different accord neuroleptic classification . The aim study compare beneficial adverse effect 3 different neuroleptic HD .</brief_summary>
	<brief_title>Neuroleptic Huntington Disease Comparison : Olanzapine , la Tetrabenazine Tiapride</brief_title>
	<detailed_description>We propose randomize controlled trial , include 180 patient , 3 group : Olanzapine , Tetrabenazine Tiapride , follow 12 month . These treatment select accord profile frequency use . The principal criterion Independence scale , one functional scale Unified Huntington 's Disease Rating Scale , validate scale HD . Secondary criterion assess motor , functional , psychiatric cognitive function , metabolic parameter , tolerance cost .</detailed_description>
	<mesh_term>Huntington Disease</mesh_term>
	<mesh_term>Tetrabenazine</mesh_term>
	<mesh_term>Olanzapine</mesh_term>
	<mesh_term>Tiapride Hydrochloride</mesh_term>
	<mesh_term>Antipsychotic Agents</mesh_term>
	<criteria>1 . Symptomatic disease motor , behavioural and/or psychiatric disorder require medical treatment . 2 . HD diagnose abnormal number CAG repeat : 38 ≤ nucleotide expansion ( CAG ) ( amendment n°5 suppress limit ≤ 48 ) 3 . Neuroleptic Prescription require . 4 . Age ≥ 18 ( amendment n°5 suppress limit ≤ 65 year old ) 5 . Patient give write consent 6 . Realization medical examination Electroencephalogram 1 . Severe cognitive impairment neuropsychiatric trouble . 2 . Existing diabetes . 3 . Neuroleptic prescription forbidden accord neurologist decision . 4 . Current participation another clinical trial . 5 . No drug compliance previous treatment . 6 . No national health insurance affiliation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Huntington</keyword>
	<keyword>Neuroleptic</keyword>
	<keyword>Unified Huntington Disease Rating Scale ( UHDRS )</keyword>
	<keyword>Independence Scale</keyword>
	<keyword>Neuroleptic Prescription require</keyword>
</DOC>